- Home
- NUVL vs GATX Comparison
NUVL vs GATX Comparison
Compare NUVL & GATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- GATX
- Stock Information
- Founded
- NUVL 2017
- GATX 1898
- Country
- NUVL United States
- GATX United States
- Employees
- NUVL N/A
- GATX N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- GATX Transportation Services
- Sector
- NUVL Health Care
- GATX Consumer Discretionary
- Exchange
- NUVL Nasdaq
- GATX Nasdaq
- Market Cap
- NUVL 5.6B
- GATX 5.6B
- IPO Year
- NUVL 2021
- GATX N/A
- Fundamental
- Price
- NUVL $70.46
- GATX $157.99
- Analyst Decision
- NUVL Strong Buy
- GATX Buy
- Analyst Count
- NUVL 10
- GATX 2
- Target Price
- NUVL $113.10
- GATX $162.50
- AVG Volume (30 Days)
- NUVL 594.2K
- GATX 148.6K
- Earning Date
- NUVL 05-08-2025
- GATX 04-22-2025
- Dividend Yield
- NUVL N/A
- GATX 1.56%
- EPS Growth
- NUVL N/A
- GATX 9.27
- EPS
- NUVL N/A
- GATX 7.78
- Revenue
- NUVL N/A
- GATX $1,585,500,000.00
- Revenue This Year
- NUVL N/A
- GATX $10.06
- Revenue Next Year
- NUVL N/A
- GATX $5.67
- P/E Ratio
- NUVL N/A
- GATX $20.15
- Revenue Growth
- NUVL N/A
- GATX 12.38
- 52 Week Low
- NUVL $61.80
- GATX $122.00
- 52 Week High
- NUVL $113.51
- GATX $168.89
- Technical
- Relative Strength Index (RSI)
- NUVL 39.36
- GATX 50.93
- Support Level
- NUVL $67.47
- GATX $153.48
- Resistance Level
- NUVL $77.93
- GATX $160.29
- Average True Range (ATR)
- NUVL 3.15
- GATX 3.06
- MACD
- NUVL -0.44
- GATX 0.41
- Stochastic Oscillator
- NUVL 26.88
- GATX 77.11
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About GATX GATX Corporation
GATX Corp is a provider of railcar leasing and maintenance services. GATX operates in business segments including rail North America, rail international, Engine Leasing, and others. The rail business offers railcar leasing and maintenance, as well as asset-related, financial, and management services. The company owns and leases fleets in North America, Europe, and Asia, which consist of tank and freight railcars. Industries served include refining and petroleum, chemicals and plastics, railroads and other transportation, mining, and food and agriculture.